High-Risk Acute Leukemia
Conditions
Interventions
Two-dimensional radiotherapy observation group:None
Helical tomographic intensity-modulated radiotherapy observation group:None
Observation group exempted from helical tomographic intensity-modulated radiotherapy for the liver and spleen:None
Sponsors
Capital Medical University Cancer Canter, Beijing Shijitan Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Age: >=18 years old, and 70 points; 3. Clinically diagnosed as acute myeloid leukemia, with no response to induction remission therapy, or recurrence within 6 to 12 months of the first remission, or recurrence after 6 to 12 months of the first remission with no response to the original induction regimen, or recurrence after two or more times; 4. Intended allogeneic hematopoietic stem cell transplantation (either fully matched or semi-matched is acceptable); 5. The subjects voluntarily joined this study, signed written informed consent forms before the implementation of any trial-related procedures, had good compliance and cooperated with the follow-up. 6. The expected survival period is more than 3 months; 7. Normal liver function (normal bilirubin, ALT/AST 50ml/min), and basically normal cardiopulmonary function.
Exclusion criteria
Exclusion criteria: 1.For research subjects without a clear diagnosis, the M3 subtype is excluded. 2. Has received radiotherapy before; 3. Enlarged liver or spleen, or imaging, cytological and other examinations suggesting liver or spleen involvement; 4. Acute myeloid leukemia transformed from myelodysplastic syndrome, etc. 5. HIV, acute infection, active hepatitis, active pulmonary tuberculosis; 6. History of dysfunction of vital organs and malignant tumors; 7. History of mental illness; 8. Has received autologous hematopoietic stem cell transplantation or organ transplantation; 9. Pregnant and lactating women and subjects of childbearing age who are unwilling to take contraceptive measures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time of hematopoietic reconstitution;30-day mortality rate after transplantation;100-day mortality rate after transplantation; | — |
Secondary
| Measure | Time frame |
|---|---|
| 12 months PFS;12 months OS;Incidence rate of interstitial pneumonia;Incidence rate of hepatotoxicity;Incidence rate of nephrotoxicity; | — |
Countries
China
Contacts
Public ContactLinan Song
Capital Medical University Cancer Canter, Beijing Shijitan Hospital
Outcome results
None listed